Proactive Investors
03 Sept 2026, 06:29 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Solvonis Therapeutics received a Notice of Allowance from the European Patent Office for a composition-of-matter patent for its lead PTSD drug candidate, SVN-114. — Composition-of-matter patents provide the strongest legal protection for pharma assets, significantly increasing the drug's valuation and attractiveness for future licensing or acquisition.
+0.60SVN-114 is part of a broader IP estate with three other chemically distinct supporting patent families already granted or allowed in the US or Europe. — Multiple layers of IP protection reduce the risk of competitors bypassing patents, strengthening the company's competitive moat.
+0.40Solvonis is funding the advancement of SVN-114 through pharmacology and safety studies via non-dilutive grants in the UK, EU, and US. — Non-dilutive funding allows the company to progress its clinical pipeline without issuing new shares, which protects existing shareholder value.
+0.30Continue reading
6 related stories
Search tags
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
1h ago
